Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Deutsche Bank AG (DB) Price & Performance

Citius Pharmaceuticals IncTrade
Deutsche Bank AGTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Deutsche Bank AG — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Deutsche Bank AG trades at $38.4 (market cap $71.96B). The key difference: Deutsche Bank AG is far larger — about 3596.2× Citius Pharmaceuticals Inc's market cap, and Deutsche Bank AG pays a 3.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRDB
Market Cap
$20.01M$71.96B
Sector
HealthFinancials
52-Week High
$1.82$40.33
52-Week Low
$0.48$28.37
Enterprise Value
$16.23M
Dividend Yield
3.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

No Aura AI signal available yet.

Deutsche Bank AG

Deutsche Bank (DB) trades at $38.27, up 0.55% today, with a bullish technical signal from moving averages. The stock shows a discounted valuation with a P/E of 10.07 and P/B of 0.79. Recent Q2 2026 earnings missed expectations at $0.66 per share versus $0.91, but revenue growth remains solid. The company announced a $1.00 dividend and a new share buyback program, supported by strong capital buffers and its recent designation as a clearing bank for China's renminbi (Reuters, 2026-08-10).

The outlook is mixed; strong operational performance and strategic initiatives like AI dealmaking (CNBC, 2026-07-29) offer upside, but earnings volatility and regulatory scrutiny (Reuters, 2026-07-22) pose risks. Analyst consensus is neutral with 57.58% hold ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Deutsche Bank AG

In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.

Read more on DB